Kyowa Hakko Kirin’s UK subsidiary is to expand its headquarters in Scotland to accommodate its growing business - at a time when other Japanese pharma companies have considered scaling back
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio